ADAMTS13 and thrombotic thrombocytopenic purpura: Despite ADAMTS13 levels in AML were not as low as in thrombocytopenic purpura (TTP) patients, ADAMTS13 activity was lower than normal and played a role in disease progression due to increased VWF levels, so the risk of excessive platelet aggregation is higher [4].